Suchergebnisse

Background:Metabolic Syndrome (MS) is a clinical entity characterized by the cluster of insulin resistance, glucose intolerance, atherogenic lipid profile, hypertension, abdominal obesity.CRP (C- reactive protein) is an acute-phase reactant and nonspecific marker of inflammation, produced predominantly in hepatocytes as a pentamer of identical subunits in response to several cytokines. The CRP in plaque deposition is highly complex, exerting pro-atherogenic effects in many cells involved in atherosclerosis. Materials and Methods:A cross sectional study was conducted by Department of Internal Medicine of Government Thanjavur Medical College Hospital, Thanjavur, Tamilnadu, South India, a tertiary care centre catering to rural population. A total of hundred patients were included in the study. The components of metabolic syndrome were defined according to the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria and World Health Organization (WHO) guidelines for South Asians.According to the guidelines, hs-CRP level of less than 1.0 mg/L is considered as low risk, 1.0 to 3.0 mg/L as moderate risk, and greater than 3.0 mg/L as high risk. Blood sample was drawn in the morning after 10 hours of fasting, to measure venous plasma glucose, serum total cholesterol, serum high density lipoprotein (HDL) cholesterol,serum triglyceride levels (TG) and hsCRP. Results:A highly positive correlation was established between hS-CRP and all the components of metabolic syndrome except for HDL cholesterol which showed a negative correlation. A univariate type of analysis had shown a statistically significant association between hsCRP and the metabolic syndrome components. The result further showed that hS-CRP level was found to be 1.12mg/dl when only one component of metabolic syndrome was present, whereas the mean level had raised to 2.89mg/dl when all the five components of metabolic syndrome was present. Conclusion:Hence hs- CRP can probably be used as a surrogate marker of chronic ...

Background : Otitis Media with Effusion(OME) also known as  Secretory Otitis Media, has been identified as the commonest middle ear condition causing deafness in children in developed countries. Neither the indication for surgical treatment nor the types and number of procedures used are uniform. Possible treatment includes myringotomy with or without insertion of ventilation tube either alone or with adenoidectomy and occasionally tonsillectomy.Aims and Objectives : To assess the prevalence and the different modes of presentation of Otitis Media with Effusion among the rural school children of Puducherry and to assess the improvement in hearing after 6 months of surgical intervention done on patients with Otitis Media with Effusion.Materials and Methods: A school screening camp was conducted on 600 children in the age group of 5-12 years in a government middle school near our medical college hospital for identifying children with Otitis Media with Effusion. Students with Otitis Media with Effusion were further classified into 4 groups for various interventional procedures namely adenotonsillectomy with bilateral grommet insertion (Group A), adenoidectomy with bilateral grommet insertion (Group B), bilateral grommet insertion (Group C), bilateral myringotomy with wide field incision in the antero-inferior quadrant (Group D).Result :The prevalence was almost in equal proportions in the age group between 5-12 years and the overall prevalence of Otitis Media with Effusion among the study population was 13.3%. The adenotonsillectomy with bilateral grommet insertion procedure had shown a significant improvement in hearing, which was measured by using pure tone audiometry by assessing the mean air-bone gap, which was 9.81, 8.27 and 6.73 at the end of 6 weeks, 3 months and 6 months respectively, when compared to the other procedures. Conclusion :Adenotonsillectomy with bilateral grommet insertion should be considered in a child with Otitis Media with Effusion who is at risk for speech/language/hearing loss.Â